Amneal Pharmaceuticals, Inc. Class A Stock

$8.41

0.12%

NYSE, Jul 07, 10:00 pm CET

ISIN

US03168L1052

Symbol

AMRX

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Amneal Pharmaceuticals, Inc. Class A Stock price

$8.41

+3.87 85.24% 5Y

NYSE, Closing price Mon, Jul 07 2025

-0.01 0.12%

ISIN

US03168L1052

Symbol

AMRX

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$2.6b

Enterprise Value

$5.1b

Net debt

$2.5b

Cash

$59.2m

Shares outstanding

313.4m

Valuation (TTM | estimate)

P/E

negative | 11.7

P/S

0.9 | 0.9

EV/Sales

1.8 | 1.7

EV/FCF

24.5

P/B

negative

Financial Health

Equity Ratio

-3.1%

Return on Equity

107.0%

ROCE

15.9%

ROIC

8.6%

Debt/Equity

-19.3

Financials (TTM | estimate)

Revenue

$2.8b | $3.1b

EBITDA

$660.6m | $676.4m

EBIT

$364.2m | $601.3m

Net Income

$-13.1m | $225.9m

Free Cash Flow

$209.2m

EPS

$0.0

FCF per Share

$0.7

Short interest

2.7%

Employees

Rev per Employee

$340.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

9x Buy

90%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,830 2,830	- 100%
- Direct Costs	1,792 1,792	- 63%
Gross Profit	1,038 1,038	- 37%
- Selling and Administrative Expenses	489 489	- 17%
- Research and Development Expense	191 191	- 7%
EBITDA	661 661	- 23%
- Depreciation and Amortization	296 296	- 10%
EBIT (Operating Income) EBIT	364 364	- 13%
Net Profit	-13 -13	- 0%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral

GlobeNewsWire

●

13 days ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a con...

Neutral

GlobeNewsWire

●

26 days ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third qua...

Neutral

GlobeNewsWire

●

about one month ago

Amneal to Participate at Upcoming Investor Conferences in June

BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and Pres...

More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office	United States
CEO	Chintu Patel
Employees	8,300
Founded	2002
Website	amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now